---
type: entity
entity_type: research_program
name: Texas IMPACT Consortium
full_name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma
domain: health
status: active
founded: 2025-12
headquarters: Texas, USA
website: null
tags: [ibogaine, OUD, PTSD, TBI, psychedelic, clinical-trial, Texas]
---

## Overview

The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total.

## Structure

**Lead institutions:** UTHealth Houston and UTMB Health (Galveston)

**Consortium members (11 institutions):**
- UTHealth Houston
- UTMB Health
- Texas Tech University
- Texas Tech UTHS El Paso
- UT Austin
- UT Health Science Center San Antonio
- UT Tyler
- UT Rio Grande Valley
- Texas A&M University
- University of North Texas Health Science Center
- Baylor College of Medicine
- JPS Health Network (Dallas)

## Research Design

**Duration:** Two-year multicenter trial (Phase 2 scale)

**Conditions targeted:**
- Opioid use disorder (primary indication) — UTHealth Houston + UTMB
- Traumatic brain injury — UT Austin + Baylor College of Medicine
- PTSD — coordinated across sites

**Key evidence basis:**
- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month
- MAPS Phase 2 OUD: 70-75% abstinence at 1 month
- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration
- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days

## Regulatory Context

**Current status:** Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US

**Safety barrier:** QT prolongation risk with >30 documented deaths in unsupervised settings

**Political support:**
- Texas SB 2308 (December 2025): Authorized $50M state funding
- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion
- Colorado Proposition 122: Decriminalized in Colorado

## Timeline

- **2025-12** — Texas SB 2308 authorizes $50M state funding for IMPACT consortium
- **2026-04** — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion

## Significance

The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history.

Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition.